Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer (CTAC)

  • End date
    May 1, 2029
  • participants needed
  • sponsor
    Peking University Cancer Hospital & Institute
Updated on 7 October 2022


The IDEA study classified stage III colon cancer into low-risk (T1-3/N1) and high-risk patients (T4 or N2) according to TNM stage. The results showed that for some low-risk patients, chemotherapy could be reduced without survival loss.

In recent years, circulating tumor DNA had achieved encouraging results in monitoring recurrence and metastasis after surgery, and has potential clinical application value. Postoperative ctDNA is also considered as a marker of increased risk of recurrence for stage I-III colon cancer and can provide predictive information for decision making on adjuvant treatment.

The results of GERCOR-PRODIGE, concomitant study of IDEA-FRANCE, showed that in the high-risk group, the patients with ctDNA positive and receiving adjuvant chemotherapy for 6 months had similar prognosis as the patients with ctDNA negative and receiving chemotherapy for 3 months; in the low-risk group, the patients with ctDNA positive but receiving chemotherapy for 3 months had worst prognosis, and the prognosis of patients with ctDNA negative chemotherapy for 3 months and 6 months and ctDNA positive chemotherapy for 6 months were similar. This indicates that risk stratification can be further performed according to the results of ctDNA after clinical pathological staging. Pathological staging is still an important decision-making factor for chemotherapy. It is not reliable to the chemotherapy decision making just based on ctDNA and abandoning clinical staging.

Therefore, a prospective, multicenter, open-label, randomized controlled clinical trial was designed aimed to investigate circulating tumor DNA guided adjuvant chemotherapy for colon cancer. In this study, all the patients are divided into high-risk group and low-risk group according to the postoperative pathology. Patients in each group were randomized to different treatment schedule according to the results of ctDNA.

Condition Colon Cancer, Circulating Tumor DNA
Treatment detection of ctDNA
Clinical Study IdentifierNCT05529615
SponsorPeking University Cancer Hospital & Institute
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Age: 18 to 75
Colon adenocarcinoma confirmed by pathology (including high and high differentiated tubular adenocarcinoma, papillary adenocarcinoma, low differentiated adenocarcinoma, mucinous adenocarcinoma and signet ring cell carcinoma)
Postoperative pathology is stage II with high-risk factors or stage III
High risk stage II refers to stage II colon cancer with at least one of the
T4 stage; b) The number of lymph nodes detected was less than 12; c) Poor differentiation (except MSI-H); d) Complicated with LVI or PNI;e) Complicated with obstruction or perforation
No distant metastasis was found in preoperative imaging examination and operation
ECOG score: 0-2 points
MSS/pMMR and BRAF wild type
Start time of chemotherapy is less than 2 months from the operation
Have sufficient organ functions
The baseline blood routine and biochemical indexes of the subject meet the following
hemoglobin ≥ 9.0 g / dl
absolute neutrophil count (ANC) ≥ 1500 / mm3
platelet count ≥ 100000 / mm3
total bilirubin ≤ 1.5 times the upper limit of normal value (ULN)
glutamic pyruvic transaminase and glutamic oxalic transaminase ≤ 2.5 times ULN
creatinine ≤ 1.5 times ULN
Patients or family members who can understand the study protocol and are willing to
participate in the study shall provide written informed consent

Exclusion Criteria

Receive chemotherapy, radiotherapy or immunotherapy before operation
History of malignant tumor in the past 5 years (except fully cured cervical carcinoma in situ or basal cell carcinoma or squamous epithelial cell skin cancer)
Pregnant women
Serious mental illness
Those with poor physical condition and difficult to complete chemotherapy
Patients or family members cannot understand the conditions and objectives of this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note